Loading...
Docoh

Horizon Therapeutics (HZNP)

Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. The Company pipeline is purposeful: it applyie scientific expertise and courages to bring clinically meaningful therapies to patients. The Company believes science and compassion must work together to transform lives.

Company profile

Ticker
HZNP
Exchange
CEO
Timothy P. Walbert
Employees
Incorporated
Location
Fiscal year end
Former names
Horizon Pharma plc, HORIZON PHARMA, INC.
SEC CIK
Subsidiaries
Horizon Medicines LLC • Horizon Ophthalmology, Inc • Horizon Orphan Holdings LLC • Horizon Orphan LLC • Horizon Properties Holding LLC • Horizon Therapeutics Brasil Ltda • Horizon Therapeutics Capital Limited • Horizon Therapeutics Finance Limited • Horizon Therapeutics Finance • Horizon Therapeutics France SAS ...
IRS number
272179987

HZNP stock data

Analyst ratings and price targets

Last 3 months
Current price
Average target
$137.50
Low target
$135.00
High target
$140.00
Morgan Stanley
Maintains
Overweight
$135.00
5 May 22
Oppenheimer
Initiated
Outperform
$140.00
15 Mar 22

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

4 May 22
17 May 22
31 Dec 22
Quarter (USD) Mar 22 Dec 21 Sep 21 Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
11 May 22 Timothy P Walbert Ordinary Shares Sell Dispose S No Yes 90 17,600 1.58M 460,549
11 May 22 Timothy P Walbert Ordinary Shares Option exercise Acquire M No No 22.14 17,600 389.66K 478,149
11 May 22 Timothy P Walbert Stock Option Ordinary Shares Option exercise Dispose M No No 22.14 17,600 389.66K 792,565
6 May 22 Timothy P Walbert Ordinary Shares Sell Dispose S No Yes 91.11 5,000 455.55K 460,549
6 May 22 Timothy P Walbert Ordinary Shares Sell Dispose S No Yes 90.33 2,400 216.79K 465,549
6 May 22 Timothy P Walbert Ordinary Shares Option exercise Acquire M No No 22.14 7,400 163.84K 467,949
6 May 22 Timothy P Walbert Stock Option Ordinary Shares Option exercise Dispose M No No 22.14 7,400 163.84K 810,165
2 May 22 Timothy P Walbert Ordinary Shares Sell Dispose S No Yes 97.43 3,450 336.13K 460,549
2 May 22 Timothy P Walbert Ordinary Shares Sell Dispose S No Yes 96.62 7,608 735.08K 463,999
2 May 22 Timothy P Walbert Ordinary Shares Sell Dispose S No Yes 95.38 13,942 1.33M 471,607
87.8% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 588 550 +6.9%
Opened positions 95 85 +11.8%
Closed positions 57 44 +29.5%
Increased positions 220 208 +5.8%
Reduced positions 204 185 +10.3%
13F shares Current Prev Q Change
Total value 21.75B 21.73B +0.1%
Total shares 201.87M 198.53M +1.7%
Total puts 750.8K 844K -11.0%
Total calls 981.39K 2.51M -60.8%
Total put/call ratio 0.8 0.3 +127.1%
Largest owners Shares Value Change
Vanguard 20.14M $2.17B +0.6%
FMR 15.87M $1.71B +1.7%
BLK Blackrock 13.01M $1.4B -3.8%
Avoro Capital Advisors 9.3M $1B +3.3%
JHG Janus Henderson 7.05M $759.95M +16.5%
Nuveen Asset Management 7.05M $759.22M +2.5%
JPM JPMorgan Chase & Co. 6.08M $655.28M +4.6%
Paulson & Co. 6M $646.56M -2.7%
STT State Street 5.47M $589.91M +0.6%
BK Bank Of New York Mellon 3.65M $392.86M -3.6%
Largest transactions Shares Bought/sold Change
Norges Bank 2.32M +2.32M NEW
Adage Capital Partners GP, L.L.C. 150K -1.76M -92.1%
Marshall Wace 1.66M +1.61M +3782.6%
WFC Wells Fargo & Co. 380.59K -1.5M -79.8%
Allspring Global Investments 1.39M +1.39M NEW
1832 Asset Management 1.41M +1.32M +1492.5%
FIL 1.83M +1.1M +150.8%
JHG Janus Henderson 7.05M +998.46K +16.5%
Renaissance Technologies 2.28M -974.4K -30.0%
Scout Investments 370.64K -844.7K -69.5%

Financial report summary

?
Management Discussion
  • Developed technology and other intangible assets, net. Developed technology and other intangible assets, net, decreased $88.1 million, from $2,960.1 million as of December 31, 2021 to $2,872.0 million as of March 31, 2022, primarily related to amortization of developed technology during the three months ended March 31, 2022.
  • In-process research and development. In April 2022, the European Commission granted marketing authorization for UPLIZNA for the treatment of adult patients with NMOSD in the European Union. As a result, we expect to reclass $70.0 million of in-process research and development to developed technology in the second quarter of 2022.
  • Goodwill. At September 30, 2021, we determined that an interim impairment analysis of the inflammation reporting unit’s $56.2 million goodwill balance was warranted. The fair value of the inflammation reporting unit exceeded its carrying value by more than 30% as of September 30, 2021, the interim testing date, resulting in no impairment. In order to evaluate the sensitivity of the fair value calculations on the goodwill impairment test, we applied a hypothetical 10 percent decrease to the fair values of the reporting unit. A 10% decrease in fair value would reduce the excess of the reporting unit’s fair value over its carrying value to approximately 19%.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. senior Avg
New words: adult, Alpine, Authorisation, batch, begun, biopharmaceutical, Brazil, CDPA, Centralised, cessation, Commerce, CPA, cultivate, DISSOLVE, Division, dual, earnout, entrant, Fisher, FL, Florida, forfeited, geopolitical, ImmTOR, immune, immunoglobulin, IND, invasion, jointly, lesser, meantime, monotherapy, Notably, notional, omicron, partnership, passage, Patheon, pediatric, pegadricase, pertaining, phenylbutyrate, philosophy, platform, Pollution, qualitative, readily, reexport, remeasured, remeasurement, retired, retirement, Russia, seropositive, settled, shortage, subside, symptomatic, Thermo, UCPA, Ukraine, unique, unrealized, uricase, Utah, variant, waned, warranted, Watson
Removed: abandoned, accumulation, achieved, adjust, Alkem, AMT, anesthesiologist, anniversary, antagonist, appeal, arrangement, ASU, ataxia, Attorney, Biomedical, Breakthrough, Carbaglu, carried, ceased, Center, Certification, CID, Circuit, Clinigen, close, closely, Collaborative, communication, compliant, component, compounded, conformity, conventional, cooperating, corneal, crystal, Curzion, CystaranTM, cystine, declined, deductibility, Delaware, delivery, derive, detail, detain, discover, dissolution, distancing, dose, draft, driver, Duchy, earned, efficient, elimination, employer, endocrinology, ENHANZE, entry, Escalation, exercisable, expensed, explanation, extinguished, extinguishment, failed, Fast, faster, Friedreich, Gaithersburg, Grand, granting, Halozyme, harder, harmonization, harmonized, Hatch, HemoShear, IMUKIN, incomplete, insight, interactive, interferon, introduce, investigation, Japanese, lab, Los, Lundquist, Lupin, Luxembourg, lysophosphatidic, majeure, Mayo, met, metabolite, mid, NBI, negotiate, newly, offshore, oncology, ophthalmic, opposed, Ops, optimal, optimize, Orange, Parliament, path, practitioner, privately, progressive, prolonged, promise, qualification, recall, receptor, recoup, red, reimbursable, removal, renamed, repatriated, repealing, repositioned, requesting, requisite, restarting, restructured, revise, revoke, SC, seize, selective, serum, shipping, shortening, shortly, Simplification, Southern, sponsor, strong, subpoena, successive, suspend, taxpayer, Tech, thirty, tied, timeline, Tolerability, Topic, track, transitioned, UCSD, unchanged, uncured, uric, Waxman

Patents

Utility
Topical Use of Levofloxacin for Reducing Lung Inflammation
17 Mar 22
The present invention relates to methods and compositions for the treatment of pulmonary inflammation.
Utility
Ado-resistant Cysteamine Analogs and Uses Thereof
27 Jan 22
The present disclosure is directed to methods for treating diseases for which cysteamine is indicated and compounds useful in such methods.
Utility
Methods for the Treatment of Thyroid Eye Disease
16 Sep 21
The invention provides a method of treating or reducing the severity of thyroid-associated ophthalmopathy (TAO), also known as thyroid eye disease (TED) or Graves' ophthalmopathy or orbitopathy (GO), as well as antibodies, or antigen binding fragments thereof, and pharmaceutical compositions comprising them, useful in the methods.
Utility
Methods for the Treatment of Scleroderma and Related Conditions
19 Aug 21
Provided herein are antibodies against insulin-like growth factor 1 receptor (IGF-1R) and their use in methods of treatment of, and achievement of clinical outcomes in, scleroderma and forms thereof, including diffuse cutaneous systemic sclerosis.
Utility
Methods for the Treatment of Thyroid Eye Disease
19 Aug 21
Provided herein are methods of treating or reducing the severity of thyroid eye disease (TED), also known as thyroid-associated ophthalmopathy (TAO), or Graves' ophthalmopathy or orbitopathy (GO), as well as antibodies, or antigen binding fragments thereof, and pharmaceutical compositions comprising them, useful in the methods.